The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences, Inc. reported that Chief Medical Officer Salomon Azoulay sold 370 shares of common stock on August 4, 2026 at a weighted average price of $65.77 per share to cover tax obligations from vesting restricted stock units under a mandatory sell-to-cover agreement, leaving 14,399 shares held directly.
MBX affiliate Peter Kent Hawryluk filed to sell 936 shares of common stock through Fidelity Brokerage Services LLC. The shares arose from restricted stock vesting on 08/03/2026 as compensation. The filing also notes a prior sale of 607 shares on 05/06/2026.
MBX filed to permit the sale of 370 shares of common stock, with an aggregate market value of $24,335.97, through Fidelity Brokerage Services LLC on NASDAQ on August 4, 2026. These shares arose from restricted stock vesting on August 3, 2026 as compensation from the issuer. The filing also lists prior sales by Salomon Azoulay in the past three months, including 231 shares for $6,824.78 on May 6, 2026 and 70,003 shares for $2,685,680.90 on May 8, 2026.
Smither John W reported acquisition or exercise transactions in this Form 4 filing.
MBX Biosciences, Inc. Chief Financial Officer John W. Smither received two equity awards on August 3, 2026. He was granted 28,000 restricted stock units that vest 25% each July 13, 2027–2030, and a stock option for 130,000 shares at $64.41 per share, vesting 25% on July 13, 2027 and monthly thereafter over 36 months, all subject to continued service.
MBX Biosciences, Inc. reported equity awards to President and CEO Steven L. Hoerter on August 3, 2026. He received stock options for 331000.0000 shares of common stock at a $64.4100 exercise price, vesting 25% on July 13, 2027 and in 36 equal monthly installments thereafter, expiring August 3, 2036. He also received 71000.0000 restricted stock units vesting 25% annually each July 13 from 2027 through 2030. Following these grants he directly held 82938.0000 common shares, while 20000.0000 additional shares are held by the Steven L Hoerter Revocable Trust, with beneficial ownership disclaimed except for any pecuniary interest.
BlackRock, Inc. reports beneficial ownership of common stock of MBX Biosciences Inc. on a Schedule 13G. BlackRock reports beneficial ownership of 2,628,181 shares of MBX common stock, representing 5.5% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,583,923 shares and sole dispositive power over 2,628,181 shares, with no shared voting or dispositive power. Various underlying persons have rights to dividends or sale proceeds, but no individual person has an interest in more than five percent of MBX’s outstanding common shares.
MBX Biosciences, Inc. reports that Chief Executive Officer and director Kent P. Hawryluk will leave both roles effective July 13, 2026. He will provide transition and strategic advisory services as a consultant through August 16, 2026. His separation terms include 12 months of base-salary severance, up to 12 months of Company-paid COBRA continuation coverage, a cash bonus equal to his target annual bonus, accelerated vesting of time-based equity that would have vested through August 16, 2027, and an extension of the post-termination stock option exercise period to July 13, 2027. The company states his departure is not due to a dispute or disagreement.
The Board appointed executive chairman Steven Hoerter as President, Chief Executive Officer and principal executive officer effective July 13, 2026, with a base salary of $665,000, a target annual bonus equal to 60% of base salary, options to purchase 331,000 shares and 71,000 RSUs, subject to multi‑year vesting. Interim Chief Financial Officer John Smither was named Chief Financial Officer and principal financial officer, effective the same date, with a $530,000 base salary, 40% target bonus, a $150,000 relocation bonus, options on 130,000 shares and 28,000 RSUs, also subject to multi‑year vesting.
MBX Biosciences ownership filing: Wellington Management Group LLP and affiliated Wellington entities report beneficial ownership of 4,977,523 shares of MBX Biosciences common stock, representing 10.46% of the class. The filing lists shared voting and dispositive powers across named Wellington entities and identifies the shares as owned of record by clients of Wellington investment advisers.
MBX BIOSCIENCES INC filed an Amendment (Schedule 13G/A) disclosing that FMR LLC beneficially owns 5,322,884.68 shares of common stock, representing 11.2% of the class as of 06/30/2026. The filing lists Abigail P. Johnson as having dispositive power over the same 5,322,884.68 shares. The report is signed under a power of attorney and references an attached 13d-1(k)(1) agreement in Exhibit 99.
MBX Biosciences reports institutional holdings disclosed on a Schedule 13G showing Paradigm-related reporting persons beneficially owning disclosed stakes as of June 16, 2026.
The filing lists Paradigm BioCapital Advisors, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. with reported sole voting and dispositive power over specified share counts. The ownership percentages use an outstanding share base of 47,597,536 shares as of May 4, 2026.